Navigation Links
National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.

MOUNTAINSIDE, N.J., May 28 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (OTC: NHGI - News) today announced that it is taking steps to change its name to Proteonomix, Inc. The change will also entail a change in its trading symbol.

Michael Cohen, President/CEO, stated: "Our new name reflects the fact that we are emerging out of our research and development stage and commencing the commercialization of our technologies. These technologies relate in great part to the identification of proteins, and their structure and functions within the emerging biotherapeutics field."

Further, the Company intends to begin marketing its current portfolio biomarkers to research laboratories globally.

National Stem Cell Holding, Inc. is focused on developing therapeutics based upon the use of human cells and their derivatives by developing proprietary stem cell therapeutics with particular focus on diabetes and cardiac diseases. Stem Cell Therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells and promises treatment of diseases previously regarded as incurable.

In addition to its work with stem cell therapeutics, it is also developing the capabilities of its wholly-owned subsidiaries: the Sperm Bank of NY (tissue bank) and in vitro fertilization (IVF) laboratory and National Stem Cell Blood Laboratories Inc. (cord blood bank) and its affiliate, ProteoDerm (anti-aging cosmetics derived from stem cells).

The Company is headquartered in Mountainside, NJ. For more information, please contact us at the company website: or .

About National Stem Cell Holding, Inc.

National Stem Cell Holding, Inc. is a hybrid biotechnology company focused on developing therapeutics based upon the use of human stem cells and their derivatives. The term 'hybrid' refers to both the business model as well its product line. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These include but are not limited to: cancer, heart disease, diabetes, neurodegenerative diseases and auto immune conditions. In addition to its work with stem cell therapeutics, the Company is leveraging its commercial infrastructure and product development capabilities of its wholly-owned subsidiaries The Sperm Bank of NY (tissue Bank and IVF laboratory) and National Stem Cell Blood Laboratories Inc. (cord blood banking program), and its affiliate, Decouverte Cosmetique, Inc.(cosmetics). The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company's multi-facetted R&D program has demonstrated results with over 10 patent applications and multiple products ready to enter the market. The Company is headquartered in Mountainside, NJ and has facilities at multiple academic institutions.

"Safe Harbor Statement"

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.


Michael Cohen

187 Mill Lane

Mountainside, NJ 07052

Phone: (212)792-6188

SOURCE National Stem Cell Holding, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Israeli Scientists Recipients of 2008 International Adult Stem Cell Award
2. BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even
3. Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada
4. MagSense to Exhibit Its Scientific and Clinical Applications at International Magnetic Carriers Conference
5. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
6. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
7. International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
10. Chindex International Announces Shelf Registration, Related Strategy and Guidance
11. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008
Post Your Comments:
(Date:11/30/2015)... MAGDEBURG, Germany , November 30, 2015 /PRNewswire/ ... in Vienna, Austria to be held ... NeuroRehabilitation (ECNR) in Vienna, Austria ... a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: ... Internet-delivered NovaVision Therapy Suite at the 3rd European Congress ...
(Date:11/30/2015)... TIKVAH, Israel , Nov. 30, 2015 /PRNewswire/ ... a leading developer of adult stem cell technologies for neurodegenerative ... Ltd., has been awarded an additional grant of approximately $735,000 ... Scientist (OCS). This grant, the second this year, brings the ... approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... ... 27, 2015 , ... Pittcon is pleased to announce the ... in symposia, oral sessions, workshops, awards, and posters. The core of the ... such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, food science, ...
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
Breaking Biology News(10 mins):